Developing a Model to Better Predict Diabetes and/or Risk of Developing Diabetes

Viome2,912 enrolled

Overview

Participants who were previously Viome costumers who signed informed consent to participate and self reported type 2 diabetes or pre-diabetes were enrolled. They provided stool samples to VIOME and were provided with precision diet and supplement recommendations. The information obtained from this study is used to train a model to predict diabetes and/or risks of developing diabetes.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

2,912

Conditions

Diabetes Type 2 Diabetes Pre-diabetes

Interventions

VIOME Precision Nutrition ProgramBEHAVIORAL

Precision diet and supplement recommendations based on participants' microbiome results.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Viome customer * GI test collected at home using Viome test kit * US citizen * 18+ years old * Is not participating in any other Viome study * Must have answered the following on-boarding question with the indicated answer: "Do you or did you ever have diabetes or prediabetes?" * Signed and dated informed consent prior to any trial-specific procedures are performed * Able to speak and read English * Willing and able to follow the trial instructions Exclusion Criteria: * Unable/unwilling to complete the informed consent form and the questionnaires

Locations (1)

Viome Research Institute

Bothell, Washington, United States

Outcomes

Primary Outcomes

Difference in VIOME's Type 2 diabetes risk score

"Type 2 diabetes risk score" is computed using Viome's molecular data from stool and HBA1C level self reported. The risk score is 1-100. 1 Indicates a low chance of developing T2D and 100 indicates a high chance of developing T2D.

Time frame: ~3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.